BioCentury
ARTICLE | Company News

Genentech, Xenon, Roche deal

March 31, 2014 7:00 AM UTC

Xenon partnered with Roche's Genentech unit to discover and validate novel targets and mechanisms to treat pain. The partners, which will both own resulting IP, will use Xenon's Extreme Genetics discovery platform to focus on rare phenotypes in which patients have an inability to perceive pain or have non-precipitated spontaneous severe pain. Genentech received a time-limited, exclusive right of negotiation on a target-by-target basis to form joint drug discovery collaborations. Xenon declined to disclose further details. Genentech said it made an upfront payment, but declined to disclose further financial terms. ...